February 07, 2012
   
Add to Google
A Super Drug for Super Bugs
email a friend print


Who are the oldest old – those 100 years of age and older? And what can these centenarians tell us about aging? More >

Follow us on Twitter. Become a fan on Facebook. Receive updates via E-mail and SMS:







Would you like to ask our staff a question? >
Join the discussion and leave a comment on this article >

A Super Drug for Super Bugs

Tom Gilbert
 
Thanks to the invention of antibiotics, 20th-century medicine virtually eliminated tuberculosis, polio, leprosy and many other once-common infectious diseases. In the 21st century, however, the advent of drug-resistant strains of tuberculosis and other killer infections — sometimes called "superbugs" — has raised fears of a frightening comeback by some of these same diseases.

So, researchers are trying a different approach. A new treatment strategy targets the so-called "virulence factors" that bacteria need to thrive once they have infected a host and offers a powerful alternative to antibiotics.

"We have developed the first inhibitor of a key small molecule from Mycobacterium tuberculosis and Mycobacterium leprae (which causes leprosy) utilized to subvert human host's defenses and damage and invade human host's cells during infection," explains senior author Dr. Luis Quadri, Associate Professor of Microbiology and Immunology at Weill Cornell Medical College in New York City. "Our next step is to explore whether this inhibitor can stop these pathogens from multiplying in a mouse host, curtailing infection."

The findings — published online and in the January 26 edition of Chemistry and Biology — may herald a massive breakthrough in infectious disease research. "We are moving beyond antimicrobials such as antibiotics, which kill the bacterium directly, to anti-infectives, that may have no effect against the pathogen in the test tube but which do compromise its ability to infect and spread in the host," Quadri explains. "We believe that the expansion of the drug armamentarium to include such anti-infective drugs could help the fight against multi-drug resistant infection that has become such a challenge today."

According to the WHO, tuberculosis kills nearly two million people every year. New drug-resistant strains of the disease — as well as even more dangerous, so-called extensive-drug-resistant (XDR) strains of the bug — are discovered each year.

"I believe that drugs targeting virulence factors are just one component of the paradigm shift in the antimicrobial drug discovery for the 21st century — one that will offer patients more options in the fight against truly global killers," Dr. Quadri says.
January 11, 2008






 
 
Add Comment
NOTE: We regret that we cannot answer personal medical questions.

Name


Comment

Characters remaining:



Readers Comments
No comments have been made







This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.





The Doctor Will See You Now   |   LEGAL RESTRICTIONS AND TERMS OF USE OF THIS SITE. USE OF THIS SITE IS YOUR AGREEMENT TO THESE TERMS.
Copyright 2012 interMDnet Corporation. All rights reserved.
About Us | Privacy Policy | Disclaimer | System Requirements